In the following video, Motley Fool health-care analyst David Williamson discusses Dendreon's (NASDAQ: DNDN) strong quarterly results that included top-line growth. Dendreon announced preliminary results in early January, so many of the numbers weren't big news, but David takes investors through key takeaways from the conference call, including progress on Dendreon's restructuring, its surprising forecast for the current quarter, and why management thinks the future is bright.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Dendreon's Big Quarter: Key Takeaways
Dendreon gets a nice boost.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and owns shares of Dendreon and Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned


*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.